<DOC>
	<DOC>NCT01850966</DOC>
	<brief_summary>To investigate the safety and efficacy of the administration of Iguratimod (CRM01T) for 52 weeks in patients with rheumatoid arthritis in clinical practice</brief_summary>
	<brief_title>Investigation of the Safety and Efficacy of Iguratimod in Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Inclusion criteria Participants with rheumatoid arthritis Participants who take iguratimod Exclusion criteria Participants registered for this survey previously Pregnant women or women suspected of being pregnant Participants with a serious liver disorder Participants with peptic ulcer Participants with known hypersensitivity to iguratimod or any of its excipients</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Arthritis, Rheumatoid, Iguratimod</keyword>
</DOC>